TP-03, 0.25% + TP-03 Vehicle

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Blepharitis

Conditions

Blepharitis

Trial Timeline

Sep 9, 2020 → May 4, 2021

NCT ID

NCT04475432

About TP-03, 0.25% + TP-03 Vehicle

TP-03, 0.25% + TP-03 Vehicle is a phase 2/3 stage product being developed by Tarsus Pharmaceuticals for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04475432. Target conditions include Blepharitis.

What happened to similar drugs?

5 of 10 similar drugs in Blepharitis were approved

Approved (5) Terminated (1) Active (4)

✅Lotilaner ophthalmic solution, 0.25% + Vehicle controlTarsus PharmaceuticalsApproved

✅AzaSite®MerckApproved

🔄TP-03 + TP-03 VehicleTarsus PharmaceuticalsPhase 3

🔄Lotilaner + Vehicle ControlLianBioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04475432	Phase 2/3	Completed	Sep 9, 2020	May 4, 2021	Blepharitis

Competing Products

15 competing products in Blepharitis

See all competitors

Product	Company	Stage	Hype Score
Lotilaner ophthalmic solution, 0.25% + Vehicle control	Tarsus Pharmaceuticals	Approved	37
TP-03 + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 3	34
Lotilaner + Vehicle Control	LianBio	Phase 3	30
ISV-305	Sun Pharmaceutical	Phase 3	40
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone	Sun Pharmaceutical	Phase 3	40
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
Azithromycin ophthalmic solution, 1% + Vehicle	Merck	Phase 2	27
Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment	Viatris	Phase 3	29
GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID	Glaukos	Phase 2	39
KPI-121 + Vehicle	Kala Pharmaceuticals	Phase 2	25